Seed · Healthtech · London, United Kingdom · Founded 2016 · 8–8 employees
NeuroHarmonics is a UCL spin-out developing wearable ultrasound devices for non-invasive treatment of brain disorders through precise neuromodulation. Their technology uses focused ultrasound to safely target deep brain circuits without requiring surgery or MRI guidance, addressing conditions like Parkinson's disease, depression, and PTSD. The company raised $2.07 million in a 2025 seed round led by Speedinvest. Their platform represents a breakthrough in making neuromodulation accessible outside of clinical settings, potentially transforming treatment from expensive invasive procedures to at-home therapy.
No open roles listed right now.